WO2001096564A3 - Isoforme d'hla-g (hla-g7) et ses applications - Google Patents

Isoforme d'hla-g (hla-g7) et ses applications Download PDF

Info

Publication number
WO2001096564A3
WO2001096564A3 PCT/FR2001/001827 FR0101827W WO0196564A3 WO 2001096564 A3 WO2001096564 A3 WO 2001096564A3 FR 0101827 W FR0101827 W FR 0101827W WO 0196564 A3 WO0196564 A3 WO 0196564A3
Authority
WO
WIPO (PCT)
Prior art keywords
hla
isoform
applications
risks
immunity
Prior art date
Application number
PCT/FR2001/001827
Other languages
English (en)
Other versions
WO2001096564A2 (fr
Inventor
Edgardo Delfino Carosella
Pascale Paul
Original Assignee
Commissariat Energie Atomique
Edgardo Delfino Carosella
Pascale Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique, Edgardo Delfino Carosella, Pascale Paul filed Critical Commissariat Energie Atomique
Publication of WO2001096564A2 publication Critical patent/WO2001096564A2/fr
Publication of WO2001096564A3 publication Critical patent/WO2001096564A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nouvelle isoforme d'HLA-G soluble (HLA-G7) et ses applications, liées à ses propriétés immunomodulatrices, pour le diagnostic des maladies autoimmunes et des risques d'avortement à répétition et le traitement, chez l'homme de troubles liés à l'immunité.
PCT/FR2001/001827 2000-06-13 2001-06-13 Isoforme d'hla-g (hla-g7) et ses applications WO2001096564A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007529A FR2810047B1 (fr) 2000-06-13 2000-06-13 Nouvelle isoforme d'hla-g et ses applications
FR00/07529 2000-06-13

Publications (2)

Publication Number Publication Date
WO2001096564A2 WO2001096564A2 (fr) 2001-12-20
WO2001096564A3 true WO2001096564A3 (fr) 2002-03-14

Family

ID=8851220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/001827 WO2001096564A2 (fr) 2000-06-13 2001-06-13 Isoforme d'hla-g (hla-g7) et ses applications

Country Status (2)

Country Link
FR (1) FR2810047B1 (fr)
WO (1) WO2001096564A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108624A2 (fr) * 2004-05-06 2005-11-17 University Of Chicago, Uctech Utilisation du genotypage hla-g dans des affections d'origine immunologiques
WO2007011044A1 (fr) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation Composition pharmaceutique comprenant un dimere hla-g lie disulfide et procede de fabrication de ce dimere hla-g lie disulfide
FR2934498B1 (fr) * 2008-08-01 2014-08-15 Commissariat Energie Atomique Utilisation d'une forme soluble d'hla-g dans le traitement des proliferations anormales des lymphocytes b.
EP2184070A1 (fr) 2008-11-07 2010-05-12 Hla-G Technologies Protéines HLA-G et leurs utilisations pharmaceutiques
US20120177671A1 (en) * 2009-06-18 2012-07-12 Hla-G Technologies Hla-g alpha 1 multimers and pharmaceutical uses thereof
EP2264067A1 (fr) 2009-06-18 2010-12-22 Hla-G Technologies Multimères de HLA-G alpha 1 et leurs utilisations pharmaceutiques
WO2010150233A2 (fr) 2009-06-25 2010-12-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Polypeptides multimères de hla-g comprenant au moins deux domaines alpha3 et leurs utilisations pharmaceutiques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (fr) * 1995-04-07 1996-10-10 The Regents Of The University Of California Anticorps pour la detection de hla-g
WO1998037098A1 (fr) * 1997-02-21 1998-08-27 Commissariat A L'energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications
WO1999042128A1 (fr) * 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
WO1999043851A1 (fr) * 1998-02-25 1999-09-02 National University Of Ireland, Cork Gene de susceptibilite a la pre-eclampsie et aux fausses-couches lie au hla
WO2000078337A1 (fr) * 1999-06-18 2000-12-28 Commissariat A L'energie Atomique Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031604A1 (fr) * 1995-04-07 1996-10-10 The Regents Of The University Of California Anticorps pour la detection de hla-g
WO1998037098A1 (fr) * 1997-02-21 1998-08-27 Commissariat A L'energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications
WO1999042128A1 (fr) * 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
WO1999043851A1 (fr) * 1998-02-25 1999-09-02 National University Of Ireland, Cork Gene de susceptibilite a la pre-eclampsie et aux fausses-couches lie au hla
WO2000078337A1 (fr) * 1999-06-18 2000-12-28 Commissariat A L'energie Atomique Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CAROSELLA, E.D. ET AL.: "HLA-G and HLA-E: fundamental and pathophysiological aspects", IMMUNOLOGY TODAY, vol. 21, no. 11, November 2000 (2000-11-01), pages 532 - 534, XP004221156 *
DATABASE EMBL 1 January 1900 (1900-01-01), ISHITANI A., GERAGHTY D. E.: "HUMAN LYMPHOCYTE ANTIGEN (HLA-G1) MRNA, COMPLETE CDS.", XP002162349, Database accession no. M90683 *
DATABASE EMBL 1 January 1900 (1900-01-01), YAMASHITA T.: "HOMO SAPIENS DNA FOR HLA-G, EXON 2.", XP002162350, Database accession no. D85032 *
DATABASE MEDLINE [online] 1999, KOMATSU, F. & YOSHIDA, S.: "Characteristics of human T-lymphotropic virus type-1 (HTLV-1)-infected cell line MT-2, which is not killed by a natural killer cell line NK-92 but is killed by lymphokine-activated killer cells", XP002185653, Database accession no. 2000074327 *
ISHITANI, A. & GERAGHTY, D.E.: "Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, no. 9, 1 May 1992 (1992-05-01), pages 3947 - 3951, XP002007028 *
ONNO, M. ET AL.: "Modulation of HLA-G Antigens Expression by Human Cytomegalovirus: Specific Induction in Activated Macrophages Harboring Human Cytomegalovirus Infection", JOURNAL OF IMMUNOLOGY, vol. 164, no. 12, 15 June 2000 (2000-06-15), pages 6426 - 6434, XP002185652 *
PAUL, P. ET AL.: "Identification of HLA-G7 as a New Splice Variant of the HLA-G mRNA and Expression of Soluble HLA-G5, -G6, and -G7 Transcripts in Human Transfected Cells", HUMAN IMMUNOLOGY, vol. 61, no. 11, November 2000 (2000-11-01), pages 1138 - 1149, XP000926217 *
ROUAS-FREIS, N. ET AL.: "The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: Is HLA-G the public ligand for natural killer cell inhibitory receptors?", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, no. 10, 13 May 1997 (1997-05-13), pages 5249 - 5254, XP002046238 *
ROUAS-FREISS, N. ET AL.: "HLA-G promotes immune tolerance", JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, vol. 14, no. 2, April 2000 (2000-04-01), pages 93 - 98, XP000926216 *
YEE, C. ET AL.: "Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Polpulations Using Peptide-MHC Tetramers", JOURNAL OF IMMUNOLOGY, vol. 162, no. 4, 15 February 1999 (1999-02-15), pages 2227 - 2234, XP002156019 *

Also Published As

Publication number Publication date
FR2810047A1 (fr) 2001-12-14
FR2810047B1 (fr) 2004-04-02
WO2001096564A2 (fr) 2001-12-20

Similar Documents

Publication Publication Date Title
WO2003057134A3 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
EP1767544A3 (fr) Méthodes de traitement des maladies inflammatoires en utilisant des liants spécifiques de l'angiopoietin-2 humain
WO2001070275A3 (fr) Conjugues de la camptothecine-acide polyglutamique et leurs procedes de preparation
AU2001228759A1 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
AU2002363797A1 (en) Compression garment for selective application of treatment of lymphedema and related illnesses manifested at various location of the body
WO2003020764A3 (fr) Facteur ix modifie
WO2001089457A3 (fr) Mimiques de thrombopoietine
WO2004048399A3 (fr) Peptides de liaison cutanee ou capillaire
AU2001239079A1 (en) Combination pro/supination and flexion therapeutic mobilization device
WO2002097130A3 (fr) Microstructures et leur utilisation pour l'evolution orientee de biomolecules
ZA9710098B (en) Halogenopyrimidines.
AUPR301001A0 (en) Compression garments and methods of use
HK1049626A1 (zh) 應用豆類產品治療外源性侵害
WO2001096564A3 (fr) Isoforme d'hla-g (hla-g7) et ses applications
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU2002240463A1 (en) Use of endostatin in the treatment of ocular neovascularization
WO2003050137A3 (fr) Mutations de recepteur de type toll 4
AU4090301A (en) Compression bandage
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
MXPA04001976A (es) Hormona de crecimiento humano modificada.
AU2001263236A1 (en) Human myd88 adapter-like protein and functional fragments thereof
WO2005011728A3 (fr) Utilisation de cd164 soluble pour les troubles inflammatoires ou auto-immuns
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
AU2001292773A1 (en) Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
AU6871501A (en) Cgi-69 compositions and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA IL JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA IL JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP